Report
29 Jul 2026
Healthy planet, healthy people: The innovative pharmaceutical industry’s contribution to the Kunming-Montreal Global Biodiversity Framework
Human health and nature are deeply interconnected. Land-use change, climate change, and pollution drive biodiversity loss and reshape the environmental conditions on which human well-being depends. Land-use change increases the risk of zoonotic spillover and emerging infectious diseases; climate change alters the distribution of vector- and waterborne diseases and stresses threatened species; and pollution adds...
Read more
Statement
15 Jul 2026
Global biopharmaceutical CEOs response to reforms introduced in Germany
In response to reforms adopted by the German government on 10 July, BCR Secretary General, and IFPMA Director General, Dr. David Reddy, said: “The legislation passed by the German government undermines the value of medical innovation, global competitiveness and patient access to new medicines. Failing to reflect the value that medicines and vaccines bring, will negatively...
Read more
Statement
6 Jul 2026
Statement on PABS Instrument at the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreement
On 6 July 2026, IFPMA delivered a statement ahead of the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreement.
Read more